This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2002;288:954.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2002;51:679

Supplies of varicella vaccine (VARIVAX®) in the United States have become sufficient to permit the resumption of the routine schedule as recommended by the Advisory Committee on Immunization Practices (ACIP).^1-3 Childcare and school attendance provisions requiring children to receive the varicella vaccine should be reinstituted.

A temporary shortage of varicella vaccine in the United States resulted from a voluntary interruption of manufacturing operations by Merck & Co., Inc., the only U.S. manufacturer of varicella vaccine.⁴ During the vaccine shortage, ACIP recommended the delay of the routine childhood varicella vaccine dose from age 12-18 months until age 18-24 months^1-2 and made additional recommendations for prioritizing use in the event of a persistent shortage.⁴

Health-care providers should review the vaccination status of their patients and administer varicella vaccine as appropriate. Recall programs for deferred unvaccinated persons should be instituted. CDC will continue to monitor vaccine supply. Updates about vaccine supply . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?